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Abstract | The discovery that repeat expansions in the C9orf72 gene are a frequent cause of 
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has revolutionized our 
understanding of these diseases. Substantial headway has been made in characterizing C9orf72-
mediated disease and unravelling its underlying aetiopathogenesis. Three main disease mechanisms 
have been proposed: loss of function of the C9orf72 protein, toxic gain of function from C9orf72 
repeat RNA or from dipeptide repeat proteins produced by repeat-associated non-ATG translation. 
Several downstream processes across a range of cellular functions have also been implicated. In this 
article, we review the pathological and mechanistic features of C9orf72-associated FTD and ALS 
(collectively termed C9FTD/ALS), the model systems used to study these conditions, and the 
probable initiators of downstream disease mechanisms. We suggest that a combination of upstream 
mechanisms involving both loss and gain of function, and downstream cellular pathways involving 
both cell-autonomous and non-cell-autonomous effects, contribute to disease progression. 
 
Introduction 
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating and fatal 
neurodegenerative diseases. In common with other neurodegenerative diseases, progress towards 
finding disease-modifying therapies in ALS and FTD has been slow, in large part owing to an 
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incomplete understanding of disease aetiopathogenesis. In 2011, ground-breaking progress was 
made with the discovery that a hexanucleotide GGGGCC repeat expansion in the C9orf72 gene (Fig. 
1) is the most frequent genetic cause of both diseases in Europe and North America1,2. Interestingly, 
C9FTD/ALS — the collective term for C9orf72-associated diseases with clinical features of FTD, ALS or 
both —is extremely rare in Asia and the Middle East3,4, indicating a different genetic architecture 
underlying FTD and ALS in these populations. The age of onset of C9FTD/ALS ranges from 27–83 
years of age3,4, and the disease duration ranges from 1–22 years3,4. C9orf72 repeat expansions have 
also been identified as a rare cause of other neurodegenerative diseases4, including Parkinson 
disease, progressive supranuclear palsy, ataxia, corticobasal syndrome, Huntington disease-like 
syndrome, Creutzfeldt–Jakob disease and Alzheimer disease. 
The vast majority (>95%) of neurologically healthy individuals have ≤11 hexanucleotide 
repeats in the C9orf72 gene5. The pathological repeat-length threshold has not been clearly defined; 
an arbitrary cut-off of 30 repeats is used in most studies, but larger expansions ranging from 
hundreds to thousands of repeats are most commonly observed in patients with C9FTD/ALS5-10. 
Importantly, the discovery of C9FTD/ALS has heightened the realization that ALS and FTD are 
intimately linked on a clinical, genetic, pathological and mechanistic spectrum. 
The expanded GGGGCC repeats are bidirectionally transcribed into repetitive RNA, which 
forms sense and antisense RNA foci11-15. Remarkably, despite being within a non-coding region of 
C9orf72, these repetitive RNAs can be translated in every reading frame to form five different 
dipeptide repeat proteins (DPRs) — poly-GA, poly-GP poly-GR, poly-PA and poly-PR — via a non-
canonical mechanism known as repeat-associated non-ATG (RAN) translation (Fig. 2)14-18. Although 
C9orf72 mutations are a relatively recent discovery, progress in understanding their pathogenenic 
effects has been rapid. Three competing but non-exclusive mechanisms have arisen: loss of function 
of C9orf72 protein, and toxic gain of function from sense and antisense C9orf72 repeat RNA or from 
DPRs. These mechanisms are all likely to contribute to disease to some extent, but it is crucial to 
determine their relative importance at various disease stages, so as to inform therapeutic strategies. 
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The differential involvement of these mechanisms might also explain clinical, pathological and 
prognostic heterogeneity that is observed in patients with C9FTD/ALS.  
In this article, we review the current understanding of the mechanisms underlying 
C9FTD/ALS, and the questions that remain unanswered. The clinical and genetic aspects of 
C9FTD/ALS have been extensively reviewed elsewhere19,20 and will not be discussed in detail here. 
 
Repeat size and somatic mosaicism 
Defining the minimum number of hexanucleotide repeats in C9orf72 that cause disease would be 
invaluable for genetic counselling and to guide disease modelling, but this issue is currently 
unresolved. Neurologically healthy individuals and patients with ALS or FTD can all have 20–30 
repeats, so whether repeat lengths within this range can drive disease is unclear. For example, a 
screen of control post-mortem brains identified an individual with 30 repeats, sparse RNA foci and 
DPR inclusions, but no neurological symptoms up until death at 84 years of age21.  
One confounding factor for accurate repeat sizing is somatic instability of the mutation. 
Individuals have been identified with large expansions within the CNS but an intermediate repeat 
length in DNA extracted from blood22-24. These studies show that >50 repeats in blood-derived DNA 
can be associated with large CNS expansions, suggesting that 50 repeats is a useful cut-off when 
analysing blood DNA. However, the current data do not support a single precise cut-off; for instance, 
70 repeats were insufficient to cause disease in an 89-year-old whose children inherited much larger 
expansions and went on to develop C9FTD/ALS25. Furthermore, defining a cut-off for blood-derived 
DNA does not help answer the key question of the minimum repeat size required in the CNS to cause 
disease.  
A further confounder is that repeat size varies between different brain regions6,10. This so-
called somatic mosaicism within the CNS might explain some of the clinical heterogeneity that is 




Pathological features of C9FTD/ALS 
TDP-43 inclusions 
The overwhelming majority of ALS cases and approximately 50% of FTD cases are characterized by 
inclusions consisting of the RNA-binding protein TDP-43 (TAR DNA-binding protein 43) in neurons 
and glia26,27. The fact that C9orf72 mutations can lead to TDP-43 inclusions (Fig. 3) in both ALS and 
FTD implies a final common pathway in these diseases28. This pathology is evident in various brain 
regions, including the frontal, temporal and primary motor cortices, hippocampus, basal ganglia, 
amygdala, thalamus and midbrain29-33. Patients with C9orf72 mutations who have a predominant ALS 
syndrome can still exhibit extramotor pathological features consistent with FTD and, conversely, 
those with a predominant FTD syndrome can show pathology in the motor system31. 
 
RNA foci 
Sense and antisense RNA foci comprising C9orf72 repeat RNA are widely distributed across the CNS 
in patients with C9FTD/ALS (Fig. 3). These foci are found predominantly within neuronal nuclei in the 
frontal and motor cortices, hippocampus, cerebellum and in the spinal cord, in motor neurons and 
occasionally in interneurons, and sporadically in the cytoplasm11,13-15,34. Less frequently, foci are 
detected in glia (astrocytes, microglia, astrocytes and oligodendrocytes 11,13,15. Sense RNA foci occur 
in ~37% and antisense foci in ~26% of neurons in the frontal cortex, respectively11,34, and they co-
occur in ~14% of frontal cortex neurons11. 
 
DPR pathology 
DPR inclusions are p62-positive and TDP-43-negative and can consist of more than one DPR (Fig. 
3)14,15,17,18,35. Several studies have examined DPRs in patients with C9orf72 repeat expansions, using 
immunohistochemistry14-18,29,35-42, immunoblotting14,16,17,38,41 or immunoassays43, and have reached 
similar conclusions. DPRs most commonly form neuronal cytoplasmic inclusions15-17,29, but can also 
exist as neuritic inclusions29,44 or as ‘pre-inclusions’15,29, which appear as diffuse cytoplasmic staining. 
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Neuronal intranuclear inclusions are sometimes observed15-17,29, and are occasionally 
paranucleolar36. Sense-derived poly-GA is the most frequent form of DPR 16,18,38-41, followed by poly-
GP then poly-GR. The antisense-derived DPRs poly-PA and poly-PR are the least frequent 
forms15,18,35,36,38-40. Although sense-derived DPRs seem to be more prevalent than antisense-derived 
DPRs in patients with C9orf72 repeat expansions, both sense-derived and antisense-derived poly-GP 
are detected in hippocampal neurons in these individuals, with strand-specific antibodies suggesting 
a preponderance of antisense-derived poly-GP14. Staining of cortical tissue with antibodies specific to 
the carboxy-terminal region of the translated DPRs revealed that translation occurs beyond the 3′ 
end of the repeats in the cortex in C9orf72 repeat expansion carriers14,18.  
DPR pathology is most prominent in the cerebellum, hippocampus and neocortex, is less 
frequent in subcortical regions, and is rarely observed in the brainstem and spinal cord. In addition, 
all DPRs can be detected in insoluble fractions from patient frontal cortex or cerebellum, as high-
molecular-weight species, indicating they are aggregation prone 14,16,17,38. A Meso Scale Discovery 
immunoassay has quantitatively detected poly-GP and poly-GA — but not, to date, any of the other 
DPRs — in both CNS tissue43 and cerebrospinal fluid (CSF)45. CSF poly-GP levels might have utility as a 
biomarker for both diagnosis and pharmacodynamic response46-48. 
 
Pathogenesis of C9FTD/ALS 
The complementary use of human tissue and in vitro and in vivo models, including illuminating 
mouse models examining both loss-of-function and gain-of-function mechanisms, has informed our 
current understanding of the contribution of C9orf72 loss of function, C9orf72 repeat RNA and DPRs 
to pathogenesis. These studies also have implicated several downstream mechanisms resulting from 





C9orf72 transcription and splicing. In C9orf72 transcript variant 2, the repeats are located within the 
promoter region (Fig. 1), so are not incorporated into variant 2 pre-mRNA but have the potential to 
affect the expression of this variant. By contrast, in variants 1 and 3, the repeats are within intron 1, 
so are included in the respective pre-mRNAs. Variant 2 is expressed at higher levels than variants 1 
and 3 in CNS tissue138,139.  
Studies have demonstrated reduced levels of one or more of the C9orf72 transcript variants  
in blood lymphocytes1,132,140, induced pluripotent stem cell (iPSC)-derived neurons12,90,94,138, frontal 
cortex1,132,141-145, cerebellum12,16,143-145, motor cortex12 and cervical spinal cord12 from C9orf72 
expansion carriers compared with controls. The findings are particularly robust for variants 1 and 
2145. C9orf72 protein levels might be correspondingly reduced in the frontal cortex110,144. Transcripts 
upstream of the repeat are increased relative to downstream transcripts in blood lymphocytes and 
brain and spinal cord tissue66 from C9orf72 expansion carriers, possibly owing to abortive 
transcription in the presence of the repeat expansion66. Raised levels of variant 1 in the frontal 
cortex and cerebellum are associated with increased survival145 — an important consideration when 
developing therapies that affect transcript levels. 
The intronic location of the repeats in variants 1 and 3 means they should be spliced out of 
the transcript, but the fact that they are translated into DPRs implies that they are either retained in 
the transcript or that the spliced intron is translated. Although levels of mature spliced C9orf72 
mRNA are reduced in the brains of individuals with C9FTD/ALS, levels of sense and antisense 
transcripts containing intron 1, where the repeats are located, are increased14,16, suggesting 
stabilization of repeat RNAs. Mature C9orf72 transcripts with correct splicing or with retention of 
intron 1 are both detected in C9FTD/ALS lymphoblasts and brain tissue138,146, indicating that both 
species contribute to RAN translation. 




Autophagy and lysosomal function. Bioinformatic analysis shows that C9orf72 is structurally related 
to the differentially expressed in normal and neoplastic cells (DENN) guanine nucleotide exchange 
factor (GEF) proteins, which activate Rab proteins. Rabs are crucial for a wide range of vesicular 
trafficking events, and multiple lines of evidence from several independent groups point to a role for 
C9orf72 in autophagy and endolysosomal trafficking and function. 
Knockdown of C9orf72 in human cell lines and primary neurons specifically inhibits 
autophagy induction, but not later stages of the autophagy pathway91,96, leading to accumulation of 
p6291,96 and cytoplasmic aggregation of TDP-4396. Consistent with these findings, accumulation of 
autophagy substrates, including p62, is observed in the spleens of C9orf72-knockout mice54,56. 
Conversely, overexpression of C9orf72 can activate autophagy, leading to an increase in 
autophagosomes in cell lines91. The role in autophagy seems to be mediated by the long C9orf72 
protein isoform (C9orf72-L) rather than the short isoform (C9orf72-S)96. The mechanism underlying 
these changes involves Rab proteins, although no consensus has been reached on which are the 
most important, with Rab1a, Rab8a and Rab39b all being implicated56,78,91,96,154. C9orf72 interacts 
with guanine nucleotide exchange protein SMCR8 and WD repeat-containing protein 41 
(WDR41)56,58,96,101,122,154, and the effect on autophagy is generally agreed to be mediated through an 
interaction with the serine/threonine-protein kinase ULK1 complex56,91,96,100,154, a key initiator of 
autophagy. Potentially, this interaction can also occur via TBK196, another serine/threonine-protein 
kinase implicated in autophagy. This finding is particularly intriguing, as loss-of-function mutations in 
TBK1 cause ALS and FTD155. 
Another link to known ALS-associated genes is through ataxin-2 (ATXN2), in which 
intermediate expansions of polyglutamine increase the risk of ALS156. C9orf72 knockdown specifically 
increases the aggregation and toxicity of ataxin-2 protein with intermediate polyglutamine repeats96.  
The relevance of the role of C9orf72 role in autophagy for disease pathogenesis is unclear, 
but neurons from patients with C9FTD/ALS have impaired basal autophagy91,93 and increased 
sensitivity to autophagy inhibition90, suggesting that reductions in C9orf72 levels contribute to 
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cellular distress. Furthermore, a Src–c-Abl pathway inhibitor, which increases autophagic processes, 
rescues survival defects in neurons derived from patients with ALS92.  
In addition to effects on autophagy, reduced endocytosis was reported in C9orf72 
knockdown cell lines78, and impaired endosomal and lysosomal trafficking were observed in bone 
marrow-derived macrophages and microglia from homozygous C9orf72 knockout mice54, as well as 
in patient-derived fibroblasts and neurons93. Moreover, C9orf72 has been shown to reside on 
lysosomes and can directly affect lysosomal function, which might also explain the effects of C9orf72 
loss of function on both endolysosomal trafficking and autophagy101. In iPSC-derived motor neurons, 
C9orf72 primarily localizes to early endosomes, and iPSC-derived motor neurons from patients with 
C9FTD/ALS have fewer lysosomes94. Both patient neurons and CRISPR–Cas9 C9orf72-knockout iPSC-
derived neurons have reduced vesicular trafficking, which can be rescued by C9orf72 
overexpression94. These cells also have elevated glutamate receptor levels and increased sensitivity 
to excitotoxicity94,127. Consistent with this observation, increased glutamate receptor levels were 
found in spinal cord tissue in a C9orf72-knockout mice94, and in spinal cord94,127 and cortical tissue94 
from patients with C9FTD/ALS.  
Taken together, these data suggest that C9orf72 is involved in multiple cellular trafficking 
events, and that loss of C9orf72 in both microglia and neurons can sensitize cells to other insults, 
thereby contributing to neurodegeneration in C9FTD/ALS. 
 
Further insights from loss-of-function mouse models. The mouse C9orf72 orthologue shares 98% 
homology with human C9orf72 and is expressed in embryonic and early postnatal neurons, various 
regions of the adult brain and spinal cord, glia, and non-neuronal tissues, including muscle, spleen, 
kidney and testes50-54,157. Several C9orf72 knockout or knockdown models have now been reported 
(Table 1)51-58.  
Transient reduction of C9orf72 expression in the CNS by antisense oligonucleotides (ASOs)13 
and conditional homozygous knockouts of C9orf72 in neurons and glia51 do not lead to motor or 
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behavioural phenotypes. By contrast, ubiquitous knockouts of C9orf7252-55,57,58 or CRISPR–Cas9-
mediated knockouts of C9orf72 isoforms56,57 throughout development led to immune system 
dysregulation in homozygous mice. The phenotypes included changes in myeloid and/or lymphoid 
cell populations in the spleen and lymph nodes, increased levels of inflammatory cytokines, and 
cervical or systemic lymphadenopathy and splenomegaly, sometimes with reduced body 
weight52,53,55,57, neoplasia55 or increased autoimmune antibody titres53,57. In comparison, 
haploinsufficiency of C9orf72 does not lead to severe phenotypes.  
Although some studies reported mild motor or cognitive phenotypes52,53 or reduced 
lifespan52,53,55,57,58 in homozygous C9orf72-knockout mice, none reported neuronal loss. 
Transcriptomic analysis confirmed changes in immune pathways53,54, similar to those observed in 
CNS tissue from patients with C9orf72 repeat expansions54. Transcriptomic analysis in human tissue 
has shown that C9orf72 transcripts are particularly prevalent in CD14+ myeloid cells, which are 
involved in innate and adaptive immunity139. Overall, in line with cellular studies of C9orf72, these 
findings suggest an important role for C9orf72 in immune regulation, possibly through its effects on 
autophagosome and lysosome function and/or microglial activity, or through alteration of 
autoimmune responses. However, in contrast to C9orf72 loss of function, knockout of other 
autophagy-related genes, including ATG7158 and ATG5159, in neurons in mice leads to 
neurodegeneration. These findings suggest that C9orf72 is not an essential component of the 
autophagy pathway that mediates neuronal survival. 
Crucially, none of the mouse C9orf72 knockouts recapitulate ALS or FTD, suggesting that 
C9orf72 loss of function is insufficient to precipitate disease. However, given the role of C9orf72 in 
pathways previously implicated in FTD and ALS160, haploinsufficiency might contribute to the disease 
process in combination with gain-of-function mechanisms, and an interesting approach will be to 





The question of whether C9orf72 repeat RNA or DPRs produced by RAN translation are the toxic 
species in aetiopathogenesis is hotly debated in the field. Various approaches, each of which has 
limitations, have been used to address this issue. Post-mortem studies generally do not capture the 
earliest pathogenic events. In vitro and in vivo models often do not feature the long repeats that are 
found in patients, owing to methodological difficulties in cloning GC-rich repeats of this length. 
Therefore, these models might not fully recapitulate the disease mechanisms. Overexpression 
models do not necessarily reflect endogenous expression levels in patients. Many models express 
expanded repeats, but as these repeats can go on to produce both C9orf72 repeat RNA and DPRs, 
attribution of downstream mechanisms to either entity is challenging. Despite these uncertainties, 
however, clear mechanistic pathways have emerged (Table 3). 
 
C9orf72 repeat RNA. In vitro, GGGGCC repeat RNA forms secondary structures, including hairpins45,66 
and highly stable G-quadruplexes45,66,161-163. Other secondary structures, including DNA–RNA 
heteroduplexes, RNA duplexes and i-motifs164-167, might arise from the sense and antisense repeat 
RNA and DNA sequences. In vivo, such secondary structures are likely to mediate the sequestration 
— and, as a consequence, depletion — of RNA-binding proteins (RBPs)66,161 (Box 2), thus providing a 
clear potential route to RNA toxicity (reviewed extensively elsewhere164,168). 
 
DPRs: insights from post-mortem studies. The results of post-mortem studies have raised suspicions 
that DPR inclusions are not the primary culprit in C9FTD/ALS pathogenesis29,35-40,43,181-183. TDP-43 
pathology and neurodegeneration co-occur in affected regions of the CNS in ALS and FTD29,35,37-39,43. 
By contrast, DPR pathology does not coincide neuroanatomically with TDP-43 pathology43 and is 
generally not found in the same neurons as TDP-43 inclusions16,29,35,40. Furthermore, DPR inclusions 
do not differ in neuroanatomical distribution between FTD and ALS cases29,37,38 and are rare in the 
spinal cord in C9orf72-associated ALS, whereas TDP-43 pathology is common14,17,18,29,36-40. DPR 
inclusions are frequent across several brain regions17,35-37,39, including structures that are thought to 
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be minimally affected in ALS and FTD, such as the cerebellum and occipital and parietal lobes. 
However, one study showed that poly-GR inclusions — but not the other DPRs — correlated with 
areas of neurodegeneration in C9orf72-associated ALS, and also, of all the DPRs, uniquely colocalized 
with TDP-43 pathology in a small sample of brains that were obtained shortly after death44. These 
data suggest that further investigation in larger, deep-phenotyped post-mortem cohorts will provide 
important insights. 
Despite these observations, strong counterarguments to support a pathogenic role for DPRs 
in C9FTD/ALS have been put forward. Post-mortem studies tend to represent the final stages of the 
disease process and might not reflect the early pathogenicity of DPRs. Aggregates observed at post-
mortem could represent protective species, and correlations with inclusions might be misleading if 
soluble species mediate neurotoxicity. CNS regions that have extensive DPR pathology but are 
unaffected by neurodegeneration might contain protective factors; indeed, selective vulnerability is 
a frequent observation in neurodegenerative diseases184.  
TDP-43 pathology is likely to be downstream of DPR pathology, probably explaining why it 
correlates more closely with neurodegeneration. This idea is consistent with downstream effects on 
TDP-43 in some experimental models expressing expanded repeats109,185 or pure DPRs106,185, 
suggesting that one or both of these gain-of-function mechanisms are linked to TDP-43. Affected 
individuals with DPR pathology but relatively mild or absent TDP-43 pathology have been 
reported16,21,43,141,182,186,187. These individuals include a young patient with evidence of intellectual 
disability186, a patient with C9orf72-associated ALS who had little extramotor TDP-43 pathology but 
showed evidence of cognitive impairment and high cerebellar DPR levels43, and patients with 
pathological or clinical diagnoses of FTLD or FTD16,141,182,186,187, some of whom died prematurely from 
other causes182. Therefore, DPR pathology without substantial TDP-43 pathology seems to be 
sufficient for disease to develop in some cases. Furthermore, as discussed below, considerable 




Insights from gain-of-function models  
Evidence for C9orf72 repeat RNA toxicity. The effects of C9orf72 repeat RNA were modelled in 
primary cortical and motor neurons transfected with expanded GGGGCC repeats within an artificial 
intronic region of the green fluorescent protein gene, reflecting the intronic human genomic context 
of C9orf72 expansions42. These neurons demonstrated nuclear RNA foci and reduced survival. Dot 
blots and immunocytochemistry revealed no DPRs in these cells, suggesting that the reduced 
survival was attributable to repeat RNA. Interestingly, however, co-expression of poly-PR and the 
intronic expanded GGGGCC repeats had a synergistic detrimental effect on neuronal survival. 
RNA toxicity has also been implicated in eye and motor neuron degeneration in a Drosophila 
model that expresses 30 GGGGCC repeats with a 6 bp (CTCGAG) interruption in the middle of the 
repeats 109,172. DPRs were not detected in the eyes or neurons, and were only detected when the 
repeats were strongly induced in all tissues109.  
One caveat for the interpretation of both studies is that the inability to detect DPRs is not 
sufficient to exclude a role for these proteins. In our experience, poly-GR can be difficult to detect 
even in flies that express this protein at high levels and show overt toxicity. Therefore, more 
sensitive detection assays for DPRs will be required to unpick the relative contributions of RNA and 
DPRs in these models. 
A study in developing zebrafish found that both sense and antisense RNA repeats could 
mediate toxicity, leading to a motor axonopathy phenotype134. No DPRs were detected in this model. 
In a Drosophila model, however, neither sense nor antisense repeats with similar lengths to those 
found in patients with C9FTD/ALS led to degeneration of adult neurons189. One potential explanation 
for this difference is that developing neurons are more susceptible to RNA toxicity than adult 
neurons. Another possibility is that RNA foci in humans sequester RBPs that are not present in 




Evidence for DPR toxicity. Two studies in Drosophila models have provided evidence that 
neurotoxicity is attributable to DPRs rather than repeat RNA138,188. In the first study, overexpression 
of expanded GGGGCC repeats in Drosophila eyes or adult neurons led to neurodegeneration188. This 
effect was inhibited when the repeats were interrupted by stop codons in each reading frame that 
prevented translation of the repeats into DPRs. The second study involved ubiquitous 
overexpression of 160 GGGGCC repeats in an intronic context, flanked by human C9orf72 
sequence138. The intron containing the repeat was spliced out and formed large numbers of sense 
RNA foci in neurons and glia, without production of DPRs. This model showed no evidence of 
neurodegeneration, reduced survival or widespread transcriptomic changes. Increasing transgene 
expression in this model led to DPR production and lifespan reduction, although the frequency of 
sense foci remained the same138, supporting the idea that DPRs rather than sense foci mediate 
neurodegeneration.  
It should be noted that although the RNA sequence interrupted by stop codons in the first 
study forms the same G-quadruplex secondary structure as uninterrupted C9orf72 repeat RNA188, 
the tertiary and quaternary structures are not necessarily identical, which might affect the dynamics 
of RBP sequestration. However, the intronic model did not have an interrupted repeat sequence and 
exhibited multiple sense foci, yet still showed no evidence of toxicity138.  
 
Toxicity of individual DPRs. In numerous studies in cell models14,42,69,87,104-106,190, Drosophila 
42,72,108,115,123, zebrafish133,134,191 and mice63,64, the repetitive GGGGCC sequence was altered to 
generate coding sequences that expressed each DPR in isolation, which was often sufficient to 
produce neurotoxicity and implicate several downstream mechanisms. The main limitation of these 
models is that DPR overexpression might not reflect the endogenous mechanisms that are seen in 
patients.  
Studies in cultured neuronal or non-neuronal cell lines or primary neuronal cultures indicate 
that poly-GR and poly-PR are the most toxic of the DPRs42,69,87,106. These arginine-rich DPRs — in 
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particular, poly-PR — are toxic to yeast.89 Poly-GA and poly-PA are also toxic, but to a lesser extent89. 
Synthetic poly-PR and poly-GR are highly toxic when exogenously applied to cultured human 
astrocytes. Poly-PR has a longer half-life than poly-GR, and is especially potent in this context68. 
Synthetic poly-GR and poly-GA are also toxic to primary neurons192. Furthermore, overexpression of 
poly-PR was found to be toxic to control iPSC-derived neurons42. 
Of all the DPRs, poly-GR had the greatest detrimental effect on development, locomotor 
activity and survival in a zebrafish model133. In Drosophila models, poly-GR and poly-PR were 
neurotoxic when expressed in the eyes42,72,108,115,123,188. In addition, flies expressing these proteins 
exhibited reduced survival42,108,123,188 and locomotor phenotypes42,123,135. Most of these studies found 
that poly-GA42,115,123, poly-PA42,188 and poly-GP108 were not toxic in Drosophila, although one study 
reported a mild reduced survival phenotype when poly-GA was expressed in adult neurons188. 
Consistent with this finding, poly-GA overexpression in cultured cells104,105, primary neurons104, 
zebrafish133,191 or mouse brain63 leads to toxicity, and synthetic poly-GA exogenously applied to 
human cells190 or primary neurons192 is also toxic. In addition, cryo-electron tomography revealed 
that poly-GA forms twisted ribbon structures that sequester the 26S proteasome107.  
Overall, these studies show that poly-GR and poly-PR are potently neurotoxic and poly-GA 
also exerts toxicity. The remaining DPRs, poly-PA and poly-GP, are unlikely to be toxic species. As 
poly-GR, poly-PR and poly-GA can all be damaging when overexpressed, a key aim is to establish the 
levels of each of these species in patient tissue, particularly at early disease stages. New techniques 





Mouse gain-of-function models. Several mouse models of C9orf72 gain of function have been 
characterized. Adeno-associated virus-mediated CNS overexpression of 66 GGGGCC repeats leads to 
motor and behavioural phenotypes by 6 months, with RNA foci, DPRs, phospho-TDP-43 inclusions 
and neuronal loss being observed59. The same approach was used to generate mice specifically 
overexpressing poly-GA in the CNS63. These mice developed neuronal cytoplasmic inclusions of 
fibrillar poly-GA, as well as neurodegeneration and motor, cognitive and behavioural phenotypes. 
However, these effects were not observed when the poly-GA sequence was mutated to a sequence 
that was unable to aggregate. Phospho-TDP-43 inclusions were rarely found; therefore, this model 
does not fully recapitulate the (GGGGCC)66 repeat mouse phenotype, indicating that species other 
than poly-GA are the main drivers of phospho-TDP-43 accumulation. A further poly-GA model, with 
expression levels more comparable to those in the cortex in patients with C9FTD/ALS, demonstrated 
motor deficits, but overall a less severe phenotype than the viral poly-GA model 64. 
 
Bacterial artificial chromosome transgenic mouse models. Bacterial artificial chromosome (BAC) 
transgenic mice have the advantages of expressing the human C9orf72 gene, with surrounding 
regulatory regions and flanking sequences, at more physiological levels. Three BAC transgenic 
models have produced similar findings. Two of these models used BAC constructs52,60, containing 
exons 1–5 of the gene and 300–500 repeats (Table 2). The third BAC model expressed the full gene 
and protein with 100–1000 repeats61. All three models developed RNA foci and DPRs in the CNS, but 
none demonstrated TDP-43 inclusion pathology, neuronal loss or reduced survival. One model 
developed memory impairment and loss of hippocampal neurons, with an increase in levels of 
phosphorylated TDP-43, but was not fully reflective of ALS or FTD52. In this model, a single injection 
of an ASO targeting C9orf72 RNA led to sustained reductions in RNA foci and DPR pathology, and 
improved cognition. Repeat length had a strong influence on the formation of RNA foci, with 100-
repeat mice developing no foci and 400-repeat mice developing many foci, despite considerably 
higher transgene expression in the 100-repeat mice52. 
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Only one study has reported BAC transgenic mice with a striking neurodegenerative 
phenotype62. The mice expressed the full gene and different repeat lengths in different lines. Three 
independent lines, two with ~500 repeats and one with high expression levels of 36 repeats, 
developed RNA foci, DPR aggregates, TDP-43 pathology and neurodegeneration. A subset of female 
mice developed an acute motor phenotype, with paralysis, weight loss and decreased survival, with 
other female and male mice showing slower progressive neurodegeneration. Antisense transcripts 
and foci were observed at especially high levels in some CNS regions that showed 
neurodegeneration, whereas sense foci were more evenly distributed. These data show that high 
expression of short repeats can be toxic, indicating that large repeats are not the critical factor for 
toxicity in this mouse model. The reason why female mice are particularly susceptible and only a 
subset develops acute disease is currently unclear, although factors such as methylation might be 
important. 
In-depth molecular and phenotypic comparisons between all the BAC models should further 
our understanding of C9orf72-associated pathogenic mechanisms. One model that expresses the 
full-length human gene with the repeat expansion recapitulates disease62 whereas the other does 
not61. These mice feature different genetic backgrounds and flanking C9orf72 sequences (Table 2), 
which might be contributory factors. Backcrossing the models that did not show a phenotype into 
different genetic backgrounds, so as to determine whether certain backgrounds facilitate disease, 
would provide new insight. 
 
Downstream mechanisms 
A range of downstream mechanisms in C9FTD/ALS have been validated across multiple human and 
non-human model systems and different laboratories (Table 3). Dysfunctional nucleocytoplasmic 
transport (NCT) is a prominent mechanism that has been identified in genome-wide screens in 




Poly-PR and poly-GR have been shown to interact with proteins that contain low complexity 
domains (LCDs), which include many RBPs72,194. LCD proteins can undergo liquid–liquid phase 
separation (LLPS) to form droplets. Through this process, the proteins become compartmentalized in 
the cell, forming membrane-less organelles such as nucleoli and stress granules. These organelles 
facilitate the assembly of RNA and RBPs into ribonucleoproteins, and also aid subsequent RNA 
metabolism. Furthermore, these LCDs can form reversible hydrogels, which have the propensity to 
fibrillize into irreversible hydrogel-like structures. Mutations frequently occur in the LCD domains in 
several RBPs that are involved in ALS, including FUS and TDP-43195. These mutations can alter the 
LLPS dynamics of RBPs, leading to their fibrillization and aggregation196-198. Poly-GR and poly-PR 
interact with LCD proteins in nucleoli and stress granules, thereby impairing LLPS, disrupting the 
dynamics of assembly of these organelles, and affecting mRNA translation and NCT72,73,82. Aliphatic 
alcohols, which disrupt phase separation and hydrogel formation, can reduce poly-PR’s protein 
interactions194 and disrupt the nucleolar localization of poly-PR and poly-GR72. Knockdown of several 
of these LCD proteins modifies the eye degeneration phenotype in a Drosophila poly-GR model72. 
Poly-PR also interacts with LCDs in intermediate filament proteins194. Interestingly, arginine-rich 
DPRs at high concentrations can undergo LLPS73. In addition, GGGGCC repeat RNA can undergo gel 
transition81,199 and induce phase transition of RNA granule proteins81 in the absence of other LCD 
proteins. These data further implicate altered LLPS in C9FTD/ALS pathogenesis. 
Effects on membrane-less organelles have been observed in several other studies. Primary 
cortical neurons that overexpress poly-PR, leading to the formation of nuclear poly-PR aggregates, 
show a reduction in cytoplasmic P-bodies and an increase in stress granule formation42. In cultured 
cells treated with arsenite, a stress granule inducer, overexpression of poly-PR and poly-GR reduced 
stress granule formation, whereas poly-GA, poly-GP and poly-PA induced stress granule formation69.  
Poly-PR interacts with translation initiation and elongation factors, and overexpression of 
poly-GR and poly-PR, but not poly-GA, inhibited translation in vitro and in cell lines87. Translational 
inhibition was attributed to direct binding of poly-GR and poly-PR to mRNA, thereby blocking access 
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to the translation machinery87. A second study also observed translational inhibition when 
(GGGGCC)31 was expressed in cell lines79. This inhibition was accompanied by an increase in stress 
granule formation (a marker of translational arrest) and nuclear accumulation of poly-A mRNAs and 
PABPc, a protein that facilitates mRNA translation in the cytoplasm79. GGGGCC repeat-induced stress 
granule formation was also observed in subsequent studies80,81. The translational inhibition might be 
explained by sequestration of PABPc by GGGGCC repeat RNA, but could also be due to the DPR-
mediated mechanisms described above. Interestingly, two studies that identified translation 
inhibition suggested that this process was independent of eukaryotic translation initiation factor 2 
subunit 1 (eIF2) phosphorylation, an important master regulator of translation that has been 
implicated in other neurodegenerative diseases200. However, stress granule induction secondary to 
poly-PR has been shown to require eIF2 phosphorylation73. 
A study published in 2018 showed that poly-GR and poly-PR induced stress granule assembly 
and localization of NCT factors into these stress granules, thereby mediating NCT dysfunction82. 
Inhibition of stress granule assembly abrogated NCT dysfunction and neurodegeneration in patient-
derived neurons and in vivo82. Stress granules and translation inhibition have been implicated in FTD 
and ALS associated with TDP-43 and FUS inclusions201, and they provide an interesting potential 
common theme across the disease spectrum. 
In three elegant studies, GGGGCC repeat overexpression constructs were used to investigate 
the mechanisms underlying RAN translation. Two of these studies showed that the integrated stress 
response, via eIF2 phosphorylation, selectively increased RAN translation80,83. Therefore, repeat-
induced cellular stress could lead to both impaired translation and enhanced RAN translation, 
causing a negative feedback loop. In addition, two of the studies showed that RAN translation 
occurred on unspliced, capped mRNA (in which the repeat-containing intron is retained), and was 
initiated by an upstream CUG acting as a start codon80,202. By contrast, the third study found that 
RAN translation occurred on the spliced intronic RNA and was cap-independent, although cap-
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dependent RAN translation was more efficient83. These mechanisms now need to be investigated in 
the context of endogenous RAN translation. 
When applied exogenously to astrocyte cultures, poly-GR and poly-PR 20mers accumulate in 
the nucleolus, leading to splicing changes and impaired ribosomal RNA (rRNA) maturation68. This 
finding led to the suggestion that these DPRs bind to and impair nuclear RBP complexes that are 
involved in mRNA splicing, which could in turn affect ribosome biogenesis and other important 
genes68. Interestingly, given the effect of poly-PR and poly-GR on NCT, splicing of RanGAP, an 
essential regulator of NCT, was altered68. Poly-PR and poly-GR also colocalize with nucleoli in 
cultured cells, primary neurons, iPSC-derived neurons and Drosophila, leading to abnormal nucleolar 
morphology36,42,67,69,71. Importantly, the brains of individuals with C9orf79-associated FTLD exhibit 
bidirectional nucleolar volume changes, with smaller neuronal nucleoli overall but enlarged nucleoli 
in neurons containing poly-GR inclusions67. Other interactome studies suggest that poly-PR and poly-
GR associate with the spliceosome component U2 snRNP in cell nuclear extracts, block spliceosome 
assembly, and disrupt splicing when applied to cell nuclear extracts85. These proteins also interact 
with mitochondrial ribosomal proteins and other ribosomal proteins117, and evidence of impaired 
mitochondrial function has been observed in iPSC-derived neurons from patients with 
C9FTD/ALS75,117. Ribosomal proteins, hnRNPs, nucleolar proteins and RBPs associated with RNA 
granules have been shown to interact with poly-GR, and overexpression of poly-GR and poly-PR led 
to decreased levels of rRNA in human cell lines69. In agreement with these data, poly-PR was shown 
to interact with proteins involved in mRNA splicing and ribosome assembly, and with ribosomal 
proteins87. Three studies have shown that in addition to effects on RNA, C9orf72 repeats can induce 
DNA damage, probably mediated by DPRs117-119.  
Overall, many cellular pathways have been implicated in gain-of-function toxicity, with the 
majority of studies focused on poly-GR and poly-PR. Given the highly toxic nature of these DPRs, 
they are likely to influence multiple pathways. Links between the downstream mechanisms and 
specific DPRs or repeat RNA have not yet been established, and sensitive techniques to measure 
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both repeat RNA and DPRs in models expressing pure GGGGCC repeats will be required to enable 
the effects of individual molecular species to be distinguished.  
Another important issue that remains to be addressed is whether different DPRs or repeat 
RNA and DPRs act synergistically, potentially in conjunction with loss of function of C9orf72, to elicit 
downstream effects. Crossing of models that express different DPR species should help to address 
this question. A further priority is to develop physiologically relevant models to reflect endogenous 
levels of C9orf72 repeat RNA and DPRs, and human iPSC-derived neuronal models will be a key tool 
in this regard. Furthermore, C9orf72 protein depletion, repeat RNA and DPRs might have non-cell-
autonomous effects, and iPSC models of neuronal, glial and muscle co-culture should increase our 
understanding of these complex interactions. 
 
Therapeutic strategies 
Targeting C9orf72 RNA or DNA 
ASOs that target C9orf72 RNA can rescue C9orf72-specific pathologies12,13,46,126, downstream gene 
expression changes12,126, NCT defects109 and TDP-43 mislocalization109 in C9orf72 fibroblasts or iPSC-
derived neurons. These ASOs also reduce NCT defects and neurodegeneration in Drosophila109 and 
diminish sense RNA foci and DPRs in mice46,52. ASO trials in humans are planned, and the feasibility 
of this strategy has a precedent in studies of superoxide dismutase 1 (SOD1)-targeting ASOs in 
patients with ALS203.  
An alternative strategy is to use compounds that target the secondary structure of C9orf72 
repeat RNA45,109,204-206. These compounds could prevent sequestration of RBPs and/or interfere with 
the RNA structure to prevent RAN translation. Such molecules have been shown to affect the 
secondary structure of C9orf72 repeat RNA in vitro45,204,206, to reduce the production of RNA foci and 
DPRs when applied to patient neurons45,205 and Drosophila205, and to rescue nuclear import defects 
and neurodegeneration in a Drosophila model109.  
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Targeting of the transcription elongation factor SPT4 reduces levels of sense and antisense 
C9orf72 repeat transcripts and ameliorates disease phenotypes in vitro and in vivo, including in 
C9orf72 iPSC-derived neurons207. Single-stranded small inhibitory RNAs have also been proposed as a 
strategy to silence the C9orf72 repeat RNA208. In addition, two studies have shown that use of the 
CRISPR–Cas9 system to target either GGGGCC repeat DNA209 — thus reducing repeat transcription — 
or repeat RNA210 can reduce RNA foci and DPR levels in cell lines. On the basis of these studies, 
targeting of C9orf72 RNA or DNA are promising strategies, and ASOs are currently the most 
advanced in terms of clinical development. 
 
Targeting DPRs and TDP-43 
In other neurodegenerative diseases, active and passive immunological approaches have been used 
to target toxic proteins such as amyloid-β211, tau212,213 and α-synuclein214,215, leading to improved 
pathology and phenotypes in model systems. With the ongoing development of specific DPR 
antibodies, passive immunization to the DPRs could present a novel therapeutic approach for 
C9FTD/ALS, and poly-GA-specific antibodies have been shown to reduce intracellular poly-GA 
aggregation and seeding activity of C9FTD/ALS brain extracts216. In addition, given that C9FTD/ALS 
pathogenesis converges on TDP-43, anti-TDP-43 immunotherapy would be a compelling strategy.  
Current strategies in other neurodegenerative diseases are based on targeting of the 
extracellular pool of protein, which is presumably involved in cell-to-cell transmission. The success of 
such an approach in the case of DPRs and TDP-43 would depend on whether there is a disease-
relevant extracellular pool to target. If not, methods to target antibodies intracellularly would be 
required. Other important factors to consider are the ideal timing of these treatments, which DPRs 
and conformations to target, the specificity and safety of the treatment, and the risks of 
precipitating an autoimmune response. As short repetitive sequences similar to DPRs are present 
across the proteome, specificity might present a barrier. Increasing clearance of DPRs by other 
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mechanisms could also be effective; for example, the small heat shock protein HSPB8 was shown to 
reduce DPR levels, probably via the autophagy pathway98. 
 
Targeting downstream mechanisms 
Targeting of downstream mechanisms might represent a useful therapeutic strategy for C9FTD/ALS. 
Reducing nuclear export by targeting the nuclear export factors SRSF1 or exportin 1 ameliorates 
toxicity in C9orf72-repeat Drosophila84,109; this was suggested to be due to either by reducing the 
levels of cytoplasmic repeat RNA (and, thus, DPRs) or by a more general mechanism to alterations in 
NCT. Importantly, in addition to the proof of concept genetic knockdown approaches that were used 
to reduce SRSF1 and exportin 1, small molecule exportin 1 inhibitors were also used, indicating a 
potential route to the clinic. It will now be important to address whether there is a large enough 
therapeutic window when targeting nuclear export, which is a fundamental cellular process.  
Inhibition of stress granule formation using either ASOs targeting Ataxin-2 or small molecules, also 
prevents NCT defects in C9-ALS iPSC-neurons and neurodegeneration in a C9orf72 repeat fly 
model82. Given the success of Ataxin-2-targeting ASOs in extending lifespan in an ALS mouse model 
overexpressing TDP-43, this strategy and the mechanisms underlying it, are of clear interest. A Src–c-
Abl pathway inhibitor that augments autophagy, improved the survival of iPSC-derived neurons from 
patients with ALS, including those with C9FTD/ALS, suggesting this approach could be beneficial for 
several forms of FTD/ALS92. Knockdown of TMX2, an endoplasmic reticulum protein that was 
identified in CRISPR–Cas9 screens in human cells and primary neurons, modulated endoplasmic 
reticulum stress in primary neurons overexpressing DPRs and increased survival of neurons derived 
from patients with C9orf72-associated ALS 88. Whether TMX2 is druggable awaits further study. High-
throughput drug screens — for example, using iPSC-derived neuronal models92,94,217 — will be of 
great importance in establishing treatments to reduce levels of repeat RNA and DPRs, repair 





Our knowledge of C9FTD/ALS has increased exponentially within a relatively short time period. 
Dissection of the disease mechanisms has not been straightforward, and the emerging picture is one 
of a combination of a diverse range of factors that lead to neurodegeneration. Given the relative 
importance of C9orf72 repeat expansions as a causative factor for ALS and FTD, rapid translation of 
the accumulated knowledge into therapeutic strategies would have a substantial impact on patients 
with these devastating neurodegenerative diseases. 
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 Rapid progress has been made in the understanding how repeat expansions in C9orf72 
cause C9FTD/ALS 
 Both loss of function of C9orf72 and gain of toxic function of the repeats are implicated 
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 A range of new models including mice, Drosophila and patient neurons have provided new 
insights 
 Several cellular pathways are affected and could provide new options for treatment 
 Targeted therapeutic strategies against the repeats themselves are most advanced and 
progressing towards clinical trials 
 
Box 1 | Epigenetic modification of C9orf72 
Analysis of blood, frontal cortex and cervical spinal cord DNA from patients with C9orf72-associated 
frontotemporal dementia and/or amyotrophic lateral sclerosis (C9FTD/ALS) has revealed that in 20–
40% of cases, the CpG island in the C9orf72 promoter region upstream of the pathogenic repeats is 
hypermethylated22,140,147,148. This hypermethylation is associated with increased repeat length and 
reduced transcription of C9orf72. Moreover, analysis of blood DNA from patients with C9FTD/ALS 
showed that in 97% of cases, the expanded hexanucleotide repeat itself was methylated148. A subset 
of C9orf72 bacterial artificial chromosome transgenic mice also demonstrate hypermethylation of 
the C9orf72 promoter and increasing hexanucleotide repeat methylation with age149. Treatment of 
C9FTD/ALS patient fibroblasts with a DNA and histone demethylating agent led to an increase in 
C9orf72 transcript levels143. Bromodomain-containing proteins are involved in epigenetic regulation, 
and bromodomain inhibitors increase C9orf72 expression in cells from patients with C9orf72-
associated ALS and control individuals150. 
Histone trimethylation is another epigenetic modification that can reduce gene expression. 
Chromatin immunoprecipitation experiments in frontal cortex and cerebellar tissue showed that the 
C9orf72 promoter region is bound to trimethylated histones in C9orf72 repeat expansion carriers143. 
Considerable evidence points to amelioration of disease phenotypes by C9orf72 
hypermethylation. Hypermethylation is associated with reductions in RNA foci and dipeptide repeat 
proteins (DPRs) in patients with C9FTD/ALS41 and C9orf72 cell models151, as well as reduced neuronal 
and grey matter loss152. In addition, hypermethylation has been linked to longer survival in patients 
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with C9orf72-associated FTD153 and a later age of onset in ALS and FTD22. However hypermethylation 
also correlates with reduced disease duration before death in patients with C9orf72-associated 
ALS140. One possibility is that some phenotypes are dependent on gain of function and others on loss 
of function, so hypermethylation could have pleiotropic effects. 
One might predict that reducing the levels of transcript variants 1 and 3 (Fig. 1) which are 
responsible for producing RNA foci and DPRs, would be protective. However, it is unclear whether 
reduction of variant 2 would be beneficial — this is the most highly expressed variant so is likely to 
be the main contributor to the functional pool of C9orf72 protein.  
 
Box 2 | RNA-binding protein sequestration 
RNA-binding proteins (RBPs) have diverse roles in splicing, translational regulation and RNA 
transport and degradation. In repeat-mediated diseases, possibly including C9orf72-associated 
disease, RBPs can become sequestered by RNA foci, leading to downstream consequences. 
A number of RBPs have been shown to interact with C9orf72 repeat RNA in human 
tissue12,66,84,169-174, in vitro assays66,84,162,170,172,174, cell models66,70,79,169,170,172,174,175, induced pluripotent 
stem cell-derived neurons12,66,126 and in vivo models79,90,169,172. The most frequently identified RBPs 
that interact with C9orf72 repeat RNA are the heterogeneous nuclear ribonucleoprotein (hnRNPs), in 
particular, hnRNP H, although hnRNP A1 and hnRNP A3 are also detected. Other RBPs include 
ALYREF, ASF/SF2, ADARB2, nucleolin, Pur-α and SRSF2. These RBPs are not found consistently across 
different studies, possibly reflecting the diversity of models and methodologies. However, several of 
these proteins have been identified in multiple independent studies, indicating that specific RBPs 
can be sequestered by GGGGCC repeat RNA. Only a small subset of RNA foci seem to colocalize with 
RBPs in human tissue170 and cells79, indicating that sequestration of these proteins is a dynamic 
process, or that diffuse C9orf72 repeat RNA that is not contained within foci can sequester RBPs. 
Overexpression of Pur-α, an RBP that is involved in transcription regulation176,177, mRNA 
localization178,179 and stress granule formation77 and was shown to interact with C9orf72 repeat 
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RNA79,172, can ameliorate neurodegeneration in C9orf72 repeat-expressing Drosophila and neuronal 
cell lines172. Overexpression of Zfp106 also supresses toxiciy in C9orf72 repeat Drosophila180. To date, 
direct evidence regarding the effects of RBP sequestration in tissue from patients with C9FTD/ALS is 
limited, although some hnRNP H targets are altered86,174. A crucial next step is to establish how the 





Figure 1 | C9orf72 structure, transcript variants and protein isoforms. The C9orf72 gene consists of 
11 exons, has three main alternatively spliced transcript variants and produces two protein isoforms. 
In the figure, coding exons are indicated in yellow and noncoding exons in blue (not to scale). The 
GGGGCC hexanucleotide repeat expansion mutation is located in the first intron of variants 1 and 3 
and within the promoter region of variant 2. Variant 1 encodes C9orf72-S (short), a 222-amino-acid 






Figure 2 | Dipeptide repeat proteins. The figure shows the dipeptide repeat proteins that are 
generated by GGGGCC repeat-associated non-ATG (RAN) translation. The sense strand generates 




Figure 3 | C9FTD/ALS neuropathology. Sense and antisense RNA foci are a common feature in the 
brains of patients with C9orf72-associated frontotemporal dementia and/or amyotrophic lateral 
sclerosis (C9FTD/ALS). a,b |Representative images show neurons from the frontal cortex of a patient 
with C9FTD/ALS, containing multiple sense (red; part a) and antisense (green; part b) foci in nuclei 
(stained blue with DAPI). Scale bar: 2.5 μm. c | TAR DNA-binding protein 43 (TDP-43) pathology in a 
patient with C9FTD/ALS. Arrow indicates a neuronal cytoplasmic TDP-43 inclusion in the frontal 
cortex, with concomitant depletion of nuclear TDP-43. Scale bar: 50 μm. d | Dipeptide repeat 
protein (DPR) pathology in a patient with C9FTD/ALS. Inclusions consisting of sense and antisense 
DPRs are produced by repeat-associated non-ATG (RAN) translation. Arrows indicate neuronal 





Figure 4 | Cellular processes implicated in C9orf72-associated FTD and ALS. A wide range of cellular 
pathways have been implicated in C9orf72-mediated disease, several of which have previously been 
linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). C9orf72 loss-of-
function and toxic gain-of-function mechanisms can both alter RNA processing and metabolism 
pathways, with alterations in stress granules and P-bodies, and C9orf72 gain-of-function 
mechanisms can lead to nucleolar dysfunction, affect RNA splicing and transcription and cause DNA 
damage. Proteostasis pathways have also been implicated, with impairments in autophagy and 
lysosomal function, the unfolded protein response and the endoplasmic reticulum, and the 
ubiquitin–proteasome system. Other cellular processes including nucleocytoplasmic transport, 
vesicular trafficking and transport granule function, and mitochondrial function, can also be 
impaired. In addition, neuron-specific processes, including hyperexcitabiliy and hypoexcitability, 
glutamate excitotoxicity, axonal transport and neuronal branching defects, have been implicated in 




Table 1 | Mouse models of C9orf72 loss of function  

















Normal function Normal function None reported  Not reported 
Panda et al. (2013)49 Non-conditional 
TALEN-mediated 
knockout  
Not reported Not reported None reported Not reported 
Suzuki et al. (2013)50 Non-conditional 
knockout of exons 
2–6 
Not reported Not reported None reported Not reported 




knockout in neurons 
and glia 
Normal function Not reported 6% reduction in 




Normal: oldest mice 
lived >24 months 
Jiang et al. (2016)52 Non-conditional 
knockout of exons 
2–6 
Mild motor deficits 










Normal until 11 
months, 7% of mice 
survived to 20 
months 
Atanasio et al. 
(2016)53 
Non-conditional 
knockout of the full 
gene 
Mild motor deficits 
at 40 weeks 
Not reported Lymphadenopathy 
at 12 months 
9 of 17 mice 
survived to the end 
of the neurological 
assay period  
O'Rourke et al. 
(2016)54 
1. Non-conditional 
knockout of exons 
2–6 
2. Non-conditional 
knockout with zinc 
finger deletion 




Sudria-Lopez et al. 
(2016)55 
Not reported — full 
knockout in all 
tissues 













Not reported Not reported Lymphadenopathy 
and splenomegaly 
Not reported 
Burberry et al. 
(2016)57 
1. Non-conditional 
knockout of exons 
2–6 in a C57BL/6 
inbred background 
(model 1) 
2. Same as model 1, 






knockout (model 3) 






Model 1: 7% alive by 
400 days 
Model 2: 64% alive 
by 300 days 
Model 3: reduced 
survival 
Ugolino et al. 
(2017)58 
Non-conditional 
knockout of exons 
2–6 
Not reported Not reported Splenomegaly and 
lethargy 
Homozygotes: >50% 
dead in 600 days  
Heterozygotes: 20% 




A range of techniques to reduce expression of or knock out the mouse C9orf72 orthologue have been used to 
investigate the normal function of C9orf72 protein. Homozygous C9orf72 knockouts suggest roles for the 





Table 2 | Mouse models of C9orf72 gain of function 
Study Mouse strain and 
methodology 



















mediated expression of 
(GGGGCC)66 repeats and 
119 bp upstream and 100 
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BAC transgenic, 140.5 kb 
upstream C9orf72 
sequence, exons 1–5, and 
































BAC transgenic, 110 kb 
upstream C9orf72 
sequence, full gene and 





























Liu et al. 
(2016)62 
FVB/NJ mice 
BAC transgenic, 52 kb 
upstream C9orf72 
sequence, full gene and 
different lines with repeat 
lengths and copy 
numbers up to 500 








increase with age 


























BAC transgenic, 140 kb 
upstream C9orf72 
sequence, exons 1–5 and 































mediated, GFP-(GA)50 or 
GFP-(GA)50-mutated 




higher than in 
(GGGGCC)66 
mice from the 

















(GA)149-CFP + 31 carboxy-
terminal amino acids 




and spinal cord, 
Similar poly-


















from endogenous human 
locus 

















mediated expression of 
10 pure or 102 
interrupted (by TCGAG 
linker) GGGGCC repeats 





























Several mouse gain-of-function models are described. The approaches used have included somatic brain or 
germline transgenesis and expression of BAC constructs containing the full-length or partial human C9orf72 
gene and repeat expansion. AAV, adeno-associated virus; BAC, bacterial artificial chromosome; C9FTD/ALS, 
C9orf72-associated frontotemporal dementia and/or amyotrophic lateral sclerosis; CFP, cyan fluorescent 
protein; DPRs, dipeptide repeat proteins; ELISA, enzyme-linked immunosorbent assay; FTLD, frontotemporal 
lobar degeneration; GFP, green fluorescent protein; pTDP-43, phospho-TDP-43; SDS, sodium dodecyl sulphate; 




Table 3 | Downstream mechanisms implicated in C9FTD/ALS  
 C9orf72 human tissue/model Other C9orf72 in 
vitro models 





















Nucleolar function/LLPS Yes66  Yes42,66,6
7 
Yes42,66 Yes68-73 Yes36 – – Yes67,72 – 
Processing bodies Yes66 – – Yes74 Yes42,74 – – – – 
Stress granules/LLPS Yes75 Yes76 Yes77 Yes69,72-
74,78-83 
Yes42,74 – – Yes72 – 
RNA processing, splicing, 
transcription and transport 
Yes84,85 Yes84-86 – Yes68,84,8
5,87,88 
Yes84 Yes89 – Yes84 – 
Nuclear speckles/LLPS – – – Yes72 – – – Yes72 – 
Cajal bodies/LLPS – – – Yes72 – – – Yes72 – 
Proteostasis 









– – – Yes54,56,5
8 




Yes80,104 – – – – 
Translational inhibition – – – Yes79,80,8
7 
– – – – – 




– – – Yes63 












Vesicle trafficking Yes93 Yes86 Yes93 Yes78,96 – – – Yes116 – 




Yes118 – – Yes117 – 
Transport granule function Yes120 Yes120 – Yes121 Yes120 – – Yes120 – 
Mitochondrial function Yes75,117 – Yes95 Yes122 – – – – – 
Notch signalling Yes123 Yes123 – – – – – Yes123 – 
Arginine methylation – – – Yes115 – – – Yes115 – 
Nervous system-specific processes 








Yes71 – – – – Yes94 





Axonal transport – – – – – – – Yes135 – 
Actin/growth cone dynamics Yes136 – – – Yes136 – – – – 
Glial dysfunction Yes137 – – – – – – – – 
Systemic functions 





Several studies (referenced within the relevant cell of the table) have identified a spectrum of downstream 
processes involved in C9orf72-mediated disease, using patient-derived tissue, cells or induced pluripotent 
stem cell-derived neurons, and in vitro or in vivo disease models. Globally, these processes can be classified 
into those involved in RNA metabolism and processing, proteostasis, other cellular processes, nervous system-





Repeat-associated non-ATG (RAN) translation 
Translation is canonically dependent on an ATG start codon for initiation. RAN translation is a non-
canonical form of translation that in the presence of repetitive sequences can start without the need 
for an ATG codon.  
 
Hairpins 
A secondary structure in which an RNA or DNA molecule folds back onto itself to resemble a hairpin. 
 
G-quadruplexes 
A secondary structure formed by guanine rich RNA or DNA molecules consisting of a stack of G-
quartets (four guanine residues aligned in a square planar configuration). 
 
i-motifs 
A four-stranded secondary structure formed by cytosine-rich DNA or RNA molecules. 
 
Frontotemporal lobar degeneration 
Frontotemporal lobar degeneration (FTLD) describes the pathological findings observed in patients 
with frontotemporal dementia (FTD), however FTLD and FTD are also often used interchangeably to 
describe the clinical syndrome. 
 
Bacterial artificial chromosome (BAC) 
 A vector for maintaining large pieces of DNA, often 50-200 kilobases in size. 
 
Cryo-electron tomography 
A high-resolution technique that involves collecting a series of tilted images of frozen hydrated 
samples using an electron microscope to produce a £D reconstruction of the sample 
 
P-bodies 
Processing bodies – membraneless organelles within the cytoplasm that are involved in translational 
repression of mRNAs and mRNA silencing and degradation  
